Dong Wha Pharm Co., Ltd.

Dong Wha Pharm Co., Ltd.

KKRX:000020
4,910.00
KRW
-460.00
(-8.57%)
527.68EPS
7.68P/E
138.87BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,835.73
7,653.03
8,038.77
8,583.72
9,362.01
11,114.85
11,118.89
9,858.88
10,608.75
12,292.01
13,042.31
16,795.92
17,887.46
18,521.63
Basic EPS, GAAP
36
177
202
949
1,700
365
330
1,033
647
736
991
201
313
652.3
Free Cash Flow per Basic Share
71.4
424.11
670.15
830.61
-719.3
-292.24
281.61
801.3
407.56
329.64
101.89
-2,820.56
-1,426.98
-161.23
Dividend per Share
79.5
70.09
80.48
80
110.05
150.12
119.93
120.05
179.92
179.9
179.95
180.26
179.79
- -
Book Value per Share
8,135.38
8,224.69
8,318.09
9,142.52
10,755.85
10,761.15
10,855.96
11,998.65
12,534.17
13,165.17
13,412.96
13,470.37
13,692.47
14,246.17
Tangible Book Value per Share
7,839.46
7,970.22
8,085.6
8,909.65
10,533.56
10,558.99
10,658.02
11,383.87
11,878.87
12,597.87
11,608.15
10,451.23
10,730.53
11,314.83
Basic Weighted Avg Shares
28
28
28
28
28
28
28
28
28
28
28
28
28
28
Sales/Revenue/Turnover
220,241
213,472
223,201
237,471
258,882
306,603
307,150
272,075
293,018
340,426
361,109
464,875
496,394
513,242
Operating Margin (%)
0.94
2.5
2.16
4.74
4.24
3.66
3.11
8.51
7.68
8.79
5.2
2.88
0.05
3.68
Depreciation Expense
12,532
12,637
11,864
11,744
11,501
11,357
11,485
10,707
12,093
12,509
13,896
19,669
21,965
22,524
Net Income, GAAP
1,012
4,937
5,609
26,254
47,009
10,069
9,116
28,508
17,870
20,383
27,438
5,563
8,686
18,076
Effective Tax Rate (%)
- -
8.6
6.53
26.37
27.92
30.75
43.92
14.64
26.18
6.47
23.59
68.91
35.99
- -
Profit Margin (%)
0.46
2.31
2.51
11.06
18.16
3.28
2.97
10.48
6.1
5.99
7.6
1.2
1.75
3.52
Working Capital
43,387
51,633
66,033
96,040
173,783
167,089
179,742
155,249
153,737
151,965
131,566
103,795
14,789
43,177
LT Debt
2,000
- -
- -
- -
- -
- -
5,116
4,075
5,056
2,044
27,883
59,795
26,325
27,176
Total Equity
227,231
229,726
230,118
252,925
296,945
297,401
299,708
342,682
360,133
378,673
402,784
401,675
401,440
415,467
Return on Invested Capital (%)
- -
2.06
1.91
3.36
2.77
2.53
1.74
5.82
4.48
7.3
3.42
0.87
0.03
- -
Return on Capital (%)
- -
2.21
2.46
10.83
17.1
3.39
3.06
8.59
4.5
5.16
6.44
2.03
3.22
- -
Return on Common Equity (%)
0.45
2.16
2.44
10.87
17.1
3.39
3.05
9.04
5.27
5.73
7.45
1.49
2.31
4.69

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
92,090
94,679
96,463
LT Borrowings
14,349
15,134
15,415
LT Finance Leases
11,976
12,424
11,761
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
173,237
161,596
138,867

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
217,615
225,828
236,730
Cash, Cash Equivalents & STI
24,374
22,005
32,492
Accounts Receivable, Net
83,010
84,506
84,731
Inventories
97,867
99,821
100,283
Total Current Liabilities
202,826
194,940
193,552
Payables & Accruals
- -
- -
- -
ST Debt
92,090
94,679
96,463
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.88%
3.25%
-0.06%
Free Cash Flow
-328.84%
-610.74%
-49.27%
Net Income, GAAP
55.96%
-2.45%
56.13%
Sales/Revenue/Turnover
8.81%
13.1%
6.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118,886
115,162
110,193
120,633
464,875
2025
125,674
125,025
121,999
123,696
496,394
2026
130,614
136,933
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
108
127
-11
-23.08
201
2025
1.24
261
34.53
16.38
313
2026
361.47
240
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180.34
- -
- -
- -
180.26
2025
- -
- -
- -
- -
179.79
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jun-Ha Yoo
Full Time Employees
838
Sector
Health technology
Industry
Pharmaceuticals: major
Address
FastFive Tower Seoul SL South Korea 04522
IPO Date
Mar 24, 1976
Business
Dongwha Pharm.Co.,Ltd is a South Korea-based pharmaceutical company engaged in the manufacture and sale of a broad range of ethical and over-the-counter (OTC) pharmaceutical products. Its main product categories include ethical drugs covering digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non-steroidal anti-inflammatory drugs (NSAIDs), respiratory system drugs, muscle relaxants, nervous system remedies, dermatological treatments, and urinary system remedies. OTC products span cold remedies, dental care, dermatological drugs, hepatic protectors, nutrients, tonics, topical analgesics, antihistamines, and anti-smoking agents. Additionally, the company offers quasi-drugs, health subsidiary foods, foods and drinks, and cosmetics. Dongwha Pharm operates primarily within South Korea but targets complex pharmaceutical market segments including both domestic consumers and healthcare providers. Founded in 1897 and headquartered in Seoul, Dongwha Pharm has recently pursued strategic expansion and diversification efforts. Notably, in 2024 the company acquired a controlling 57.8% stake in Hironic Co., an aesthetic medical device manufacturer specializing in high-intensity focused ultrasound (HIFU) and radiofrequency (RF) devices. This acquisition marks Dongwha Pharm’s entry into the high-growth aesthetic medical device market, aiming to diversify and enhance its medical device portfolio for global competitiveness. In 2023, Dongwha Pharm also acquired a 51% stake in Vietnam’s Trung Son Pharma to facilitate entry into the Southeast Asian pharmaceutical and beauty markets, with plans to grow Trung Son’s pharmacy network to 460 stores by 2026 and introduce Korean products including herbal drinks, functional foods, cosmetics, and OTC drugs. Strategic partnerships further strengthen Dongwha Pharm’s market position. The company signed a strategic partnership with Henkel Home Care Korea, and its battery materials affiliate Dongwha Electrolyte formed a collaboration with U.S.-based Elementium Materials to commercialize a new electrolyte product targeting advanced battery markets. Dongwha Pharm continues leveraging its established pharmaceutical portfolio alongside these partnerships and acquisitions to secure diversified growth streams and enhance competitive positioning in both domestic and international markets. The company also benefits from a robust product pipeline that includes small molecule drugs, biologicals, and approved therapeutic products in areas such as hemophilia and diabetes. Dongwha Pharm’s product offerings and market expansion are supported by longstanding brand presence, including recognized cold medicine brands like Pancold S, which has led the market for consecutive years. Despite operating largely in the mature South Korean market, the company is pursuing geographic diversification via acquisitions and strategic alliances in Southeast Asia and is expanding into high-potential adjacent sectors such as aesthetic medical devices. These efforts reflect Dongwha Pharm’s focus on maintaining steady domestic demand while pursuing growth opportunities through innovation and market expansion. In summary, Dongwha Pharm.Co.,Ltd produces and markets a wide range of pharmaceutical and health-related products, complemented by recent major changes including acquisition of Hironic Co. to enter aesthetic medical devices, the takeover of a majority stake in Vietnam’s Trung Son Pharma for regional expansion, and strategic partnerships to enhance product innovation and production capabilities. The company operates mainly in South Korea but is expanding its footprint in Southeast Asia and adjacent healthcare sectors. Founded in 1897 and headquartered in Seoul, Dongwha Pharm remains a significant player in the pharmaceutical industry focused on ethical and OTC drug markets alongside emerging medical device and health product opportunities.